Results of NCI melanoma trial for CTLA-4+vaccine

[Olga]

Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade.
http://clincancerres.aacrjournals.org/c ... 13/22/6681

A total of 139 patients with metastatic melanoma were treated by CTLA-4 (ipilimumab) in conjunction with peptide vaccinations at the Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland and the result is:
Three patients achieved complete responses (CR; ongoing at 29+, 52+, and 53+ months); an additional 20 patients achieved partial responses (PR) for an overall objective response rate of 17%.
Immune-related adverse events were associated with a greater probability of objective antitumor response; all patients with CR had more severe immune-related adverse events. Prior therapy with IFN{alpha}-2b was a negative prognostic factor.